HO151DLBCL: The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL
The prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients. Toxicity data on atezolizumab are available for > 6000 patients and is manageable. The assumption of this study is that atezolizumab consolidation will result in higher disease free survival by eradicating minimal residual disease In melanoma and lung cancer consolidation immunotherapy after chemoradiotherapy has shown an increase in survival.
In high risk diffuse large B-cell lymphoma (DLBCL), International Prognostic Index (IPI)-score ≥ 3 21% of patients will relapse within 2-years after completion of R-CHOP induction treatment despite achieving a complete remission. Patient relapsing within a year after R-CHOP treatment have a very poor prognosis, even after second line chemotherapy, with only 15% of patients achieving a long remission. Therefore, additional therapy in first line treatment is required for these patients. The immune checkpoint inhibitor atezolizumab is a monoclonal antibody directed against the program death ligand 1 (PDL1). The PD1 and PDL1 inhibitors have shown excellent results in relapsed Hodgkin lymphoma and promising results in relapsed B-cell non Hodgkin lymphoma. Given the acceptable toxicity profile of atezolizumab, this study examines the efficacy and toxicity of atezolizumab as consolidation treatment after R-CHOP induction in DLBCL patients at high risk of relapse.
Arms and Interventions
18 cycles atezolizumab followed by 12 months of observation
Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation
Primary Outcome Measures
- Disease free survival (DFS) measured from the date of registration to relapse or death from any cause whichever comes first. [2 year after inclusion last patient]
To evaluate the 2-year DFS for patients in complete metabolic remission after R-CHOP induction
Secondary Outcome Measures
- (Severe) Adverse Events and the relation of adverse events in time to the recovery of the T-cell repertoire. [2 years after inclusion last patient]
To evaluate toxicity and assess the relation of adverse events in time to recovery of the T-cell repertoire.
- Overall survival (OS), calculated from registration until death from any cause. Patients still alive or lost to follow up are censored at the last date known to be alive. [2 years after inclusion last patient]
To evaluate the 2-year OS.
- The relationship between MRD status at the end-of-induction and end-of-consolidation therapy. [2 years after inclusion last patient]
To evaluate MRD status at the end of induction therapy, at various time points during consolidation treatment and at the end of consolidation.
- The relation between MRD conversion and 2-years DFS and OS. [2 years after inclusion last patient]
To evaluate if there is a relation between MRD conversion and 2-years DFS and OS.
- The relation between the T-cell and NK cell repertoire and adverse events. [2 years after inclusion last patient]
To evaluate the recovery of the T-cell and NK cell repertoire after induction therapy and at various time points during consolidation treatment in relation to toxicity and efficacy.
Other Outcome Measures
- Atezolizumab spinal fluid concentration as assessed by spinal fluid measurements will be performed in patients receiving atezolizumab. [2 years after inclusion last patient]
To assess the crossing of the blood-brain barrier of atezolizumab by measuring atezolizumab concentrations in het cerebrospinal fluid.
Age 18-75 (inclusive) years
Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma (DLBCL-NOS) based upon a representative histology specimen according to the World Health Association (WHO) classification, revision 2016
Ann Arbor stages II-IV
WHO performance status 0 - 1
International Prognostic Index (IPI) ≥ 3 at diagnosis
Complete metabolic remission (Deauville 1-3) after 6-8 cycles of R-CHOP according to the Lugano criteria
Rituximab may have been administered either intravenously or subcutaneously. A rituximab biosimilar may have been used when it is approved for the indication of DLBCL.
Patients should have received at least 6 cycles R-CHOP. Dose reductions for vincristine are allowed during R-CHOP. Dose reductions because of bone marrow toxicity are allowed but cannot exceed >15% of cumulative dose of doxorubicin and cyclophosphamide.
Central nervous system prophylaxis (MTX) by intrathecal therapy or IV is allowed.
Fludeoxyglucose Positron Emission Tomography (18F-FDG-PET) scan should have been made 4-8 weeks after last induction cycle
Histologically confirmed false positive EoT PET-scans are eligible.
Negative pregnancy test at study entry
Patient is willing and able use adequate contraception during and until 5 months after the last protocol treatment.
Patient is capable of giving a written informed consent
• All histopathological diagnoses other than DLBCL-NOS according to the WHO classification, revision 2016, including:
High-grade B-cell lymphoma with a double/triple translocation with MYC, BCL2 and/or BCL6. Please note that patients with an isolated MYC translocation or an isolated BCL2 translocation or an isolated BCL-6 translocation are eligible (single hit translocation).
Testicular large B-cell lymphoma
Primary mediastinal B cell lymphoma
Transformed indolent lymphoma
Post-transplant lymphoproliferative disorder
Clinical signs of severe pulmonary dysfunction
Clinical signs of heart failure (New York Heart Association (NYHA) classification II-IV)
Symptomatic coronary artery disease or cardiac arrhythmias not well controlled with medication.
Myocardial infarction during the last 6 months
Significant renal dysfunction (serum creatinine ≥ 150 umol/l or clearance ≤ 30ml/min
Creatinine clearance (CrCl) may be calculated by Cockcroft -Gault formula:
CrCl = (140 - age [in years]) x weight [kg] (x 0.85 for females)/(0.815 x serum creatinine [μmol/L])
• Inadequate hematological function: hemoglobin < 5.5 mmol/L Absolute Neutrophil Count (ANC) < 1.0x10↑9/L or platelets < 75x10↑9 /L
Signs or known history of bleeding disorder.
Significant hepatic dysfunction (total bilirubin ≥ 1.5x upper limit of normal (ULN) or transaminases ≥ 2.5 x ULN), unless related to Gilberts syndrome.
Clinical signs of severe cerebral dysfunction
Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
Major surgery within the last 4 weeks
Known or suspected infection • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks of the start of Cycle 1. Suspected active or latent tuberculosis needs to be confirmed by positive interferon gamma (IFN-γ) release assay
• Patients known to be Human Immuno-deficiency Virus (HIV)-positive
Active chronic hepatitis B or C infection
Administration of a live, attenuated vaccine within 4 weeks before date of registration or anticipation that such a live attenuated vaccine will be required during the study and for a period of 5 months after discontinuation of atezolizumab
Auto-immune • Any active or history of documented autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
The following exceptions are allowed: Patients with autoimmune-related hypothyroidism or type 1 diabetes mellitus who are on stable treatment.
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest computer tomography (CT) scan at screening.
Patients with uncontrolled asthma or allergy, requiring systemic steroid treatment
Regular treatment with corticosteroids within the 4 weeks prior to date of registration, unless administered for indications other than NHL at a dose equivalent to < 30 mg/day prednisone/prednisolone
• Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease)
• Current participation in another clinical trial interfering with this trial
• History of active cancer during the past 5 years, except basal cell carcinoma of the skin, stage 0 cervical carcinoma or carcinoma in situ (for which no systemic treatment was indicated)
• Life expectancy < 6 months
• Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Prior treatment with Atezolizumab, or anti-programmed cell death protein-1 (anti PD-1) or PDL-1 antibodies.
Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA4 therapeutic antibodies.
Treatment with systemic immunostimulatory agents (including but not limited to IFN, interleukin [IL]-2) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1.
Treatment with systemic immunosuppressive medications, including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) agents within 2 weeks prior to date of registration; inhaled corticosteroids and mineralocorticoids are allowed.
Contacts and Locations
|12||NL-Den Bosch-JBZ||Den Bosch||Netherlands|
|13||NL-Den Haag-HAGA||Den Haag||Netherlands|
Sponsors and Collaborators
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Principal Investigator: M. Nijland, PhD/MD, NL-Groningen-UMCG
Study Documents (Full-Text)None provided.